BSX · News · 20260807N

Guidance / Outlook

BOSTON SCIENTIFIC CORP · 2026-08-07 · Importance 47 · Surprise 60

Third-party reporting says Boston Scientific cut its 2026 guidance after weakness in the WATCHMAN business, electrophysiology share losses, and delayed margin improvement. The reports characterize the reduction as postponing a broader recovery toward 2028. No revised revenue, margin, or earnings amounts were provided in the digest.

Key facts

• Analysts and investors are advised to monitor future earnings calls for updates on sales guidance and any impacts on procedure volumes, particularly in electrophysiology, due to the recalls. source